dm+d
83490000
Articles
RMOC Hydroxychloroquine retinopathy monitoring: Consultation running until 20/11/2020
19 October 2020Advice was requested from the Regional Medicines Optimisation Committee (RMOC) regarding the most appropriate and practical approach for the ophthalmology monitoring of patients who are…
What advice should be given to patients with porphyria who intend to travel?
20 December 2019Most travel vaccines are safe in the acute porphyrias, but there has been an unpublished report of an acute porphyria attack following yellow fever vaccination.…
Medicine Compliance Aid Stability
PlaquenilSanofi
Sanofi
Plaquenil
Tablets 200mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light in airtight container.
11 February 2015
genericBristol Labs
Bristol Labs
generic
Tablets 200mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light in airtight container.
11 February 2015
Lactation Safety Information
See summary
Moderate amount of published evidence of safety
Small amounts in breast milk
Very long half-life increases risk of accumulation in breastfed infants with prolonged treatment in mother
If appropriate, monitor infant for ocular effects, e.g. uveitis
Avoid in known G6PD deficiency, hyperbilirubinaemia, and in jaundiced premature infants because of risk of kernicterus
18 September 2018